Major Randomized Clinical Trials in Giant Cell Arteritis
The landmark 2017 tocilizumab trial (GiACTA) represents the most significant breakthrough in GCA treatment, demonstrating superior glucocorticoid-sparing efficacy compared to glucocorticoids alone, and forms the basis for current ACR/Vasculitis Foundation guideline recommendations. 1
Key Pivotal Trials
Tocilizumab (GiACTA Trial - 2017)
The GiACTA trial published in 2017 established tocilizumab as the first biologic with proven efficacy in GCA, showing significant glucocorticoid-sparing effects and higher sustained remission rates compared to placebo plus glucocorticoids 1
Study design: Patients were randomized to subcutaneous tocilizumab 162 mg weekly plus 26-week prednisone taper (TCZ-QW), tocilizumab every-other-week plus 26-week taper (TCZ-Q2W), placebo plus 26-week taper, or placebo plus 52-week taper 2
Key findings: Only one-fifth of patients treated with glucocorticoids alone achieved sustained remission, while tocilizumab groups demonstrated significantly better outcomes 3
Relapse patterns: Among 149 tocilizumab-treated patients, 24% experienced flares (64% still on prednisone at median 2.0 mg/day), compared to 58% of 101 placebo-treated patients experiencing flares (76% on prednisone at median 5.0 mg/day) 2
Important caveat: Most flares (92%) in tocilizumab-treated groups occurred with normal CRP levels, indicating acute-phase reactants are unreliable indicators of disease activity in patients receiving IL-6 blockade 2
Methotrexate Trials
Three randomized controlled trials evaluated methotrexate as a glucocorticoid-sparing agent, but results have been conflicting and inconsistent 1
Meta-analysis findings: A 2021 systematic review found no significant benefit for methotrexate in reducing relapse rates at week 52, with low to very low quality of evidence 4
Current positioning: Methotrexate can be considered for patients unable to use tocilizumab due to recurrent infections, history of gastrointestinal perforations/diverticulitis, or cost constraints 1
Upadacitinib (SELECT-GCA Trial - 2025)
The most recent major trial (2025) evaluated upadacitinib, a selective JAK inhibitor, in patients with new-onset or relapsing GCA 5
Study design: 428 patients randomized 2:1:1 to upadacitinib 15 mg daily, 7.5 mg daily (both with 26-week glucocorticoid taper), or placebo with 52-week glucocorticoid taper 5
Primary endpoint results: Upadacitinib 15 mg achieved sustained remission in 46.4% vs 29.0% with placebo (P=0.002), demonstrating superiority 5
Dose-response relationship: The 7.5 mg dose (41.1% sustained remission) did not show superiority over placebo, indicating 15 mg is the effective dose 5
Safety profile: No major adverse cardiovascular events occurred in upadacitinib groups during the 52-week treatment period, though cardiovascular risk remains a theoretical concern with JAK inhibitors 5
Other Biologic Trials
Infliximab: One randomized controlled trial showed no efficacy in recent-onset disease, though an open study suggested potential benefit in glucocorticoid-resistant disease 6
Etanercept and adalimumab: Single trials each evaluated these TNF inhibitors without demonstrating significant benefit 7
Abatacept: Can be considered if tocilizumab and methotrexate are not effective, though evidence is limited 1
Comparative Efficacy Evidence
Network Meta-Analysis (2022)
Tocilizumab demonstrated superiority over methotrexate with a relative risk of relapse of 0.41 (95% CI 0.17-0.97) 7
Tocilizumab vs glucocorticoids: Significantly lower relapse risk compared to both prolonged (RR 0.41,95% CI 0.20-0.83) and short (RR 0.32,95% CI 0.16-0.66) glucocorticoid regimens 7
Methotrexate vs glucocorticoids: No significant difference in relapse risk with either short or prolonged glucocorticoid use 7
Safety comparison: Frequency of serious adverse events and serious infections was comparable between different drugs, though certainty of evidence was low to very low 7
Systematic Review Findings (2021)
Only the anti-IL-6/IL-6 receptor drug class showed reduced relapse risk at week 52 (RR 0.45,95% CI 0.30-0.66), particularly tocilizumab (RR 0.38,95% CI 0.23-0.63) with moderate quality evidence 4
No significant interaction by glucocorticoid tapering regimen was found, suggesting benefit is independent of steroid taper speed 4
Clinical Implications from Trial Data
Treatment Timing
- Benefits of tocilizumab plus prednisone over prednisone alone become apparent by 8 weeks, indicating early disease control with combination therapy 2
Monitoring Challenges
Acute-phase reactants are unreliable in tocilizumab-treated patients: 92% of flares occurred with normal CRP levels in the GiACTA trial 2
More than half of placebo-treated patients had elevated CRP without clinical flares, highlighting the poor specificity of inflammatory markers 2
Relapse Patterns
Most relapses occur while patients are still receiving prednisone, with 25% of tocilizumab-treated and 22% of placebo-treated patients experiencing flares on >10 mg/day prednisone 2
Approximately 50% of patients on glucocorticoid monotherapy and 30% receiving tocilizumab experience relapses, often within the first 2 years after diagnosis 8
More than 50% of patients relapse after tocilizumab discontinuation, suggesting IL-6 blockade suppresses disease activity but does not restore immune tolerance 8
Common Pitfalls
Do not rely solely on CRP/ESR for monitoring disease activity in patients receiving tocilizumab or other IL-6 inhibitors, as these markers are suppressed independent of true disease activity 2
Recognize that even high-dose glucocorticoids (>10 mg/day) do not prevent all relapses, necessitating consideration of steroid-sparing agents early in the disease course 2
Understand that tocilizumab's lack of long-term follow-up data and cost may limit its use, though it remains the most evidence-based steroid-sparing option 1